Eysz: Gaining Insight into Epilepsy

article image

Eysz aims to transform epilepsy care with an AI-based clinical decision support software solution that analyzes passive eye movement data, enabling clinicians to make informed treatment decisions, rather than depend on unreliable patient self-reported information.

The costs of treating epilepsy have risen dramatically each year. Compared to a decade ago, direct costs related to the condition have increased nearly 100% to $28 billion annually. Concerningly, this rise in patient expenses doesn’t correlate with an improvement in outcomes, which have remained at a stagnant rate since the 1990s.

Contributing to this lack of progress is the primary diagnostic tool used in determining seizure medication dosage for epilepsy: patient-self-reported data, which studies have shown to have an accuracy rate of 50% or less. Unreliable data leads to more hospital visits, and for a patient, fear about the stability of their own condition. Not to mention, the pressure of diligent self-tracking and self-reporting can be intrusive to a patient’s lifestyle.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: